×
About 1,323,300 results

Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease
https://www.e-jmd.org/upload/jmd-19082.pdf
Journal of Movement Disorders;

We recruited 228 drug-naïve PD patients who were followed for a mean of 6 years. Patients underwent the Cross-Cultural Smell Identification Test (CCSIT), a neuropsychological test, and N-(3-[18F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane positron emission tomography within 6 months of the baseline evaluation. Olfactory dysfunction was categorized as normosmia (CCSIT score ≥ 9)...

Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033758/

Levodopa-induced dyskinesia (LID) is the most common, disruptive complication of Parkinson’s disease (PD) pharmacotherapy, yet despite decades of research, the changes in regional brain function underlying LID remain largely unknown. We previously found that the cerebral vasomotor and metabolic responses to levodopa are dissociated in PD subjects. Nonetheless, it is unclear whether levodopa-med...

The serotonergic system in Parkinson’s patients with dyskinesia: evidence from imaging studies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060863/

The purpose of review is to review the current status of positron emission tomography (PET) molecular imaging of serotonergic system in Parkinson’s patients who experience levodopa-induced (LIDs) and graft-induced dyskinesias (GIDs). PET imaging studies have shown that Parkinson’s disease is characterized by progressive loss of dopaminergic and serotonergic neurons. Parkinson’s patients who exp...

Dopamine Transporter Density in de novo Parkinson's Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901354/

In Parkinson’s disease (PD), the onset of levodopa-induced dyskinesias (LIDs) is difficult to predict. This study examines whether dopamine transporter (DAT)-specific SPECT imaging in de novo PD relates to later development of LIDs.

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)
https://jamanetwork.com/journals/jamacardiology/fullarticle/2768916

Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection
https://jamanetwork.com/journals/jamacardiology/fullarticle/2770645

Myocarditis is a significant cause of sudden cardiac death in competitive athletes and can occur with normal ventricular function.1 Recent studies have raised concerns of myocardial inflammation after recovery from coronavirus disease 2019 (COVID-19), even in asymptomatic or mildly symptomatic patients.2 Our objective was to investigate the use of cardiac magnetic resonance (CMR) imaging in com...

Challenges in the interpretation and application of typical imaging features of COVID-19
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30233-2/fulltext
The Lancet Respiratory Medicine;

18F-DCFPyL–PET/CT Imaging Improves Diagnostic Capability in Relapsed Prostate Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200168/full/

May 28th, 2020 - Imaging with 18F-DCFPyL–PET/CT was found to be diagnostically effective, often guiding a change in treatment plan, in men with biochemically relapsed prostate cancer, according to the results of the phase III CONDOR study presented during the ASCO20 Virtual Scientific Program (Abstract 5501).

PSMA-Targeted PET Tracer Outperforms Standard Diagnostic Modalities in Relapsed Prostate Cancer
https://www.targetedonc.com/view/psma-targeted-pet-tracer-outperforms-standard-diagnostic-modalities-in-relapsed-prostate-cancer

May 29th, 2020 - 18F-DCFPyL-PET/CT imaging outperfomed standard imaging modalities, including bone scan, CT, MRI, and FDG PET, in patients with biochemically relapsed prostate cancer, according to the phase 3 CONDOR study.

PyL PET Tracer May Be Superior to Standard Imaging for Prostate Cancer
https://www.targetedonc.com/view/pyl-pet-tracer-may-be-superior-to-standard-imaging-for-prostate-cancer

May 29th, 2020 - PSMA-targeted 18F-DCFPyL-PET/CT imaging demonstrated excellent diagnostic performance in men with biochemically relapsed prostate cancer in terms of a correct localization rate that far exceeded the criteria to meet the primary end point, according to findings from the phase 3 CONDOR trial.

Imaging in Parkinson’s disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280219/
Clinical Medicine;

The clinical presentation of Parkinson’s disease (PD) is heterogeneous and overlaps with other conditions, including the parkinsonian variant of multiple system atrophy (MSA-P), progressive supranuclear palsy (PSP) and essential tremor. Imaging of the brain in patients with parkinsonism has the ability to increase the accuracy of differential diagnosis. Magnetic resonance imaging (MRI), single ...

Diagnostic Performance of PSMA-Targeted PET Tracer Excels in Relapsed Prostate Cancer
https://www.onclive.com/conference-coverage/asco-2020/diagnostic-performance-of-psma-targeted-pet-tracer-excels-in-relapsed-prostate-cancer

May 29th, 2020 - Imaging with 18F-DCFPyL-PET/CT outperformed that of standard imaging modalities—such as bone scan, CT, MRI, and FDG PET—in patients with biochemically relapsed prostate cancer in the phase 3 CONDOR trial.

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
https://www.nature.com/articles/s41531-018-0069-x
NPJ Parkinson's Disease;

Levodopa-induced dyskinesias (LID) negatively impact on the quality of life of patients with Parkinson’s disease (PD). We assessed the risk factors for LID in a cohort of de-novo PD patients enrolled in the Parkinson’s Progression Markers Initiative (PPMI). This retrospective cohort study included all PD patients enrolled in the PPMI cohort. Main outcome was the incidence rate of dyskinesia, de...

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-morris-on-the-impact-of-psma-targeted-imaging-on-clinical-management-of-prostate-cancer/

May 31st, 2020 - Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).

Improved Treatment Response Following Magnetic Resonance Imaging–Guided Focused Ultrasound for Lumbar Facet Joint Pain
https://www.sciencedirect.com/science/article/pii/S2542454819301535

Magnetic resonance imaging–guided focused ultrasound (MRgFUS) is a noninvasive modality that allows for precise tissue ablation with sparing of surrounding structures. Early reports of the use of MRgFUS for the treatment of facet joint osteoarthritis are promising. We present a case of facet joint pain treated successfully by MRgFUS at our institution. Magnetic resonance imaging–guided focused ...

Alcohol Intoxication and Cognition: Implications on Mechanisms and Therapeutic Strategies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029710/

Binge alcohol drinking is highly prevalent in young adults and results in 30% deaths per year in young males. Binge alcohol drinking or acute alcohol intoxication is a risk factor for developing alcohol use disorder (AUD). Three FDA approved drugs are currently in use as therapy for AUD; however, all of them have contra-indications and limitations. Structural brain imaging studies in alcoholics...

National Institute of Biomedical Imaging and Bioengineering (NIBIB)
https://www.nibib.nih.gov/

The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care.

Highlighting COVID-19 Blood Clot Dangers
https://www.uspharmacist.com/article/highlighting-covid19-blood-clot-dangers

Based on recent reports that demonstrated a strong association between elevated D-dimer levels and poor prognosis, concerns have risen about thrombotic complications in patients with COVID-19. To address these concerns, the National Institute for Public Health of the Netherlands asked a group of radiology and vascular medicine experts to provide guidance for the imaging workup and treatment of ...

Thermal Imaging Systems (Infrared Thermographic Systems / Thermal Imaging Cameras)
https://www.fda.gov/medical-devices/general-hospital-devices-and-supplies/thermal-imaging-systems-infrared-thermographic-systems-thermal-imaging-cameras
US Food and Drug Administration (FDA)

As discussed further below, scientific studies support that certain telethermographic systems, also known as thermal imaging systems, may be used to measure surface skin temperature. These systems include an infrared thermal camera and may have a temperature reference source. In this document, they are referred to as thermal imaging systems.

NIH-funded COVID-19 home test is first to receive over-the-counter authorization from FDA
https://www.nibib.nih.gov/news-events/newsroom/nih-funded-covid-19-home-test-first-receive-over-counter-authorization-fda
National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Dec 14th, 2020 - The U.S. Food and Drug Administration granted emergency use authorization (EUA) today for an innovative COVID-19 viral antigen test developed with support from the National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) Initiative.